
Holly Rachael Keir

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1051826/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 1 | High Frequency of Allergic Bronchopulmonary Aspergillosis in Bronchiectasis-COPD Overlap. Chest, 2022, 161, 40-53. | 0.8 | 8 |
| 2 | Sputum Proteomics in Nontuberculous Mycobacterial Lung Disease. Chest, 2022, 161, 1180-1191. | 0.8 | 8 |
| 3 | Characterization of Eosinophilic Bronchiectasis: A European Multicohort Study. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 894-902. | 5.6 | 67 |
| 4 | Neutrophil extracellular traps in chronic lung disease: implications for pathogenesis and therapy. European Respiratory Review, 2022, 31, 210241. | 7.1 | 44 |
| 5 | Bronchiectasis enters the inflammation era. Respirology, 2022, 27, 488-489. | 2.3 | 3 |
| 6 | Endotyping Chronic Obstructive Pulmonary Disease, Bronchiectasis, and the "Chronic Obstructive Pulmonary Disease–Bronchiectasis Association― American Journal of Respiratory and Critical Care Medicine, 2022, 206, 417-426. | 5.6 | 29 |
| 7 | Non-COVID-19 respiratory viral infection. Breathe, 2022, 18, 210151. | 1.3 | 3 |
| 8 | The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2021, 147, 158-167. | 2.9 | 102 |
| 9 | A high-risk airway mycobiome is associated with frequent exacerbation and mortality in COPD. European Respiratory Journal, 2021, 57, 2002050. | 6.7 | 44 |
| 10 | Integrative microbiomics in bronchiectasis exacerbations. Nature Medicine, 2021, 27, 688-699. | 30.7 | 105 |
| 11 | The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study. Lancet Respiratory Medicine,the, 2021, 9, 885-896. | 10.7 | 63 |
| 12 | SPLUNC1 is a novel marker of disease severity and airway infection in bronchiectasis. European Respiratory Journal, 2021, 58, 2101840. | 6.7 | 3 |
| 13 | Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study. Lancet Respiratory Medicine,the, 2021, 9, 873-884. | 10.7 | 99 |
| 14 | Inhaled Corticosteroids and the Lung Microbiome in COPD. Biomedicines, 2021, 9, 1312. | 3.2 | 18 |
| 15 | Highlights of the ERS Lung Science Conference and Sleep and Breathing Conference 2021 and the new ECMC members. Breathe, 2021, 17, 210080. | 1.3 | 0 |
| 16 | IL-6 trans-signalling: how Haemophilus surfs the NET to amplify inflammation in COPD. European Respiratory Journal, 2021, 58, 2102143. | 6.7 | 1 |
| 17 | Less is more? Antibiotic treatment duration for exacerbations of bronchiectasis. European Respiratory Journal, 2021, 58, 2101416. | 6.7 | 2 |
| 18 | ERS ECM Awardee 2021, a preview of LSC 2022 and a brief overview of the Respiratory Channel. Breathe, 2021, 17, 210121. | 1.3 | 0 |

HOLLY RACHAEL KEIR

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin. ERJ Open Research, 2020, 6, 00583-2020. | 2.6 | 19 |
| 20 | Increased Chitotriosidase Is Associated With Aspergillus and Frequent Exacerbations in South-East Asian Patients With Bronchiectasis. Chest, 2020, 158, 512-522. | 0.8 | 15 |
| 21 | Blood neutrophil counts are associated with exacerbation frequency and mortality in COPD. Respiratory Research, 2020, 21, 166. | 3.6 | 44 |
| 22 | Antimicrobial peptides, disease severity and exacerbations in bronchiectasis. Thorax, 2019, 74, 835-842. | 5.6 | 43 |
| 23 | Pregnancy Zone Protein Is Associated with Airway Infection, Neutrophil Extracellular Trap Formation, and Disease Severity in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 992-1001. | 5.6 | 42 |
| 24 | A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and riskÂofÂexacerbation. European Respiratory Journal, 2019, 53, 1900303. | 6.7 | 50 |
| 25 | Airway Bacterial Load and Inhaled Antibiotic Response in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 33-41. | 5.6 | 70 |
| 26 | Early Career Members at the Lung Science Conference and the Sleep and Breathing Conference 2019. Breathe, 2019, 15, 234-240. | 1.3 | 0 |
| 27 | Distinct "lmmunoallertypes―of Disease and High Frequencies of Sensitization in Non–Cystic Fibrosis Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 842-853. | 5.6 | 57 |
| 28 | Circulating desmosine as a biomarker of azithromycin treatment response: a <i>post hoc</i> analysis of the COLUMBUS randomised controlled trial. ERJ Open Research, 2018, 4, 00136-2018. | 2.6 | 0 |
| 29 | Immunological corollary of the pulmonary mycobiome in bronchiectasis: the CAMEB study. European Respiratory Journal, 2018, 52, 1800766. | 6.7 | 105 |
| 30 | Profile of the ProAxsis active neutrophil elastase immunoassay for precision medicine in chronic respiratory disease. Expert Review of Molecular Diagnostics, 2017, 17, 875-884. | 3.1 | 10 |
| 31 | 10â€years since TORCH: shining a new light on the risks of inhaled corticosteroids in COPD. European Respiratory Journal, 2017, 50, 1701582. | 6.7 | 9 |
| 32 | The past decade in bench research into pulmonary infectious diseases: <scp>W</scp> hat do clinicians need to know?. Respirology, 2017, 22, 1062-1072. | 2.3 | 9 |
| 33 | ERS International Congress 2021: highlights from the Respiratory Infections Assembly. ERJ Open Research, 0, , 00642-2021. | 2.6 | 0 |